Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note released on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

NASDAQ:TTNP opened at $6.97 on Tuesday. Titan Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $16.60. The stock has a 50 day moving average of $7.36 and a two-hundred day moving average of $7.16. The firm has a market cap of $6.34 million, a P/E ratio of -0.85 and a beta of 1.33.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.